Glenmark Pharma Q3 net beats forecast, up 1.5% to Rs 216 cr

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Moneycontrol Bureau

Mumbai-based Glenmark Pharma reported 1.5 percent growth year-on-year in profits and 16 percent in revenues for the quarter ended December 2013.

Numbers were better than analysts' expectations, though the net profit for the quarter is not comparable due to out-licensing income of Rs 49.3 crore reported in the previous corresponding quarter.

Year-on-year consolidated net profit increased to Rs 216.2 crore from Rs 213 crore and revenue rose to Rs 1,601.2 crore from Rs 1,382 crore. Analysts had expected a 14 percent degrowth in bottomline at Rs 184 crore and 13.2 percent growth in topline at Rs 1,565 crore for the quarter.

Consolidated earnings before interest, tax, depreciation and amortisation or operating profit grew 14 percent on yearly basis to Rs 365 crore while operating profit excluding out-licencing income jumped 34.75 percent in the quarter gone by.

Operating profit margin fell 40 basis points year-on-year to 22.8 percent as against expectations of 160 basis points decline.

Revenue from the generics business climbed 24.73 percent to Rs 737.3 crore while specialty formulation business excluding out-licensing revenue grew 16.62 percent to Rs 864 crore compared to a year ago period. Both were in-line as analysts had estimated generic business to grow 25 percent and specialty formulation over 15 percent.

"Despite challenges in the operating environment, we have registered good growth in both speciality and generics businesses across the globe," Glenn Saldanha, chairman and MD said.

He is reasonably confident of maintaining growth trajectory with emerging markets businesses being a key growth driver going ahead.

Specialty business

Revenues from formulation business in India rose 15.27 percent to Rs 381.23 crore while sales from Africa, Asia and CIS region (Rest of the World) grew 14.89 percent to Rs 300.96 crore compared to corresponding quarter of last fiscal.

Glenmark’s revenue from Latin American and Caribbean operations soared 12 percent to Rs 113.93 crore year-on-year and European operations expanded 45.27 percent to Rs 67.84 crore.

Generics Business

In case of generics business, USA registered revenue growth of 19.43 percent Y-o-Y at USD 521.36 crore from sale of finished dosage formulations while European formulations business surged 72.08 percent to Rs 68 crore in the quarter gone by.

Revenue from sale of active pharmaceutical ingredients (API) to regulated and semi-regulated markets globally jumped 28.5 percent to Rs 147.9 crore compared to a year ago period.